Celgene (NASDAQ:CELG) has been assigned a $128.00 price objective by equities research analysts at Mizuho in a research note issued on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price target indicates a potential upside of 21.92% from the company’s current price.
A number of other equities research analysts have also commented on the company. Bank of America lowered Celgene from a “buy” rating to a “neutral” rating and upped their target price for the company from $104.68 to $120.00 in a research report on Friday. UBS Group lowered Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 target price on the stock. in a research report on Thursday, October 26th. BMO Capital Markets dropped their target price on Celgene from $163.00 to $148.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Royal Bank of Canada reiterated a “buy” rating and issued a $147.00 target price on shares of Celgene in a research report on Thursday. Finally, Jefferies Group reiterated a “buy” rating and issued a $160.00 target price on shares of Celgene in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and twenty have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $131.53.
Shares of Celgene (NASDAQ CELG) traded down $1.69 during mid-day trading on Friday, hitting $104.99. The stock had a trading volume of 10,582,028 shares, compared to its average volume of 6,674,910. Celgene has a 1-year low of $94.55 and a 1-year high of $147.17. The stock has a market capitalization of $82,660.00, a price-to-earnings ratio of 24.76, a price-to-earnings-growth ratio of 0.71 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.
Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the previous year, the firm earned $1.58 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. equities analysts expect that Celgene will post 6.69 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the business. Thompson Davis & CO. Inc. raised its position in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI raised its position in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares in the last quarter. Robecosam AG acquired a new stake in shares of Celgene during the 3rd quarter worth about $114,000. Guidant Wealth Advisors acquired a new stake in shares of Celgene during the 3rd quarter worth about $119,000. Finally, Capital Bank & Trust Co raised its position in shares of Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 517 shares in the last quarter. 79.74% of the stock is currently owned by institutional investors.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.